Vicore Pharma Holding AB (VCRE) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-74.9%

$2.41

vs $9.59 price

Levered DCF

$2.49

After debt service

Piotroski score

—

Altman Z-score

—

Rating

C-

Overall 1 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021
P/E	-68.09×	-163.42×	-51.14×	-44.5×	-31.25×
P/B	3.28×	0×	0×	0×	0×
P/S	941.48×	22.5×	0×	0×	0×
EV / EBITDA	-6.32×	0×	0×	0×	0×
Gross margin	100.0%	100.0%	0.0%	0.0%	0.0%
Operating margin	-11905.8%	-174.1%	0.0%	0.0%	0.0%
Net margin	-12509.1%	-154.2%	0.0%	0.0%	0.0%
Current ratio	10.28×	0×	0×	0×	0×
Debt / equity	0×	0×	0×	0×	0×
Interest coverage	-7,574.08×	-23,795×	-160,753×	-36,340.63×	0×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Return on equity	-43.6%	0.0%	0.0%	0.0%	0.0%
Return on invested capital	-41.3%	0.0%	0.0%	0.0%	0.0%
Return on assets	-39.2%	0.0%	0.0%	0.0%	0.0%
Free cash flow yield	-10.5%	-6.7%	-15.8%	-24.8%	-25.8%
Earnings yield	-13.3%	-6.9%	-19.7%	-23.6%	-28.8%
Enterprise value	$3B	$0	$0	$0	$0
Net debt / EBITDA	1.21×	0×	0×	0×	0×
Cash conversion cycle (days)	0	0	0	0	0